International Association for the Study of Lung Cancer: Breakthrough Therapy BAY 2927088 Demonstrates 'Rapid, Substantial and Durable Responses' in Patients With HER2-Mutant NSCLC
September 10, 2024
September 10, 2024
AURORA, Colorado, Sept. 10 (TNSres) -- The International Association for the Study of Lung Cancer issued the following news release:
(San Diego, Calif.--September 9, 2024, 10:05 a.m.) -- Treatment with BAY 2927088 led to rapid, substantial, and durable responses in patients with heavily pretreated HER2-mutant non-small cell lung cancer (NSCLC), according to research presented today at the International Association for the Study of Lung Cancer 2024 World Conference on Lung Cancer.
(San Diego, Calif.--September 9, 2024, 10:05 a.m.) -- Treatment with BAY 2927088 led to rapid, substantial, and durable responses in patients with heavily pretreated HER2-mutant non-small cell lung cancer (NSCLC), according to research presented today at the International Association for the Study of Lung Cancer 2024 World Conference on Lung Cancer.